证券代码：688553 证券简称：汇宇制药 公告编号：2025-073 四川汇宇制药股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次会议是否有被否决议案：无 一、会议召开和出席情况 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况： ■ （四）表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次会议由公司董事会召集，由公司董事长丁兆先生主持，采用现场投票和网络投票相结合的方式召 开。本次会议的召集、召开程序符合《公司法》、《证券法》、《公司章程》的规定。 （五）公司董事、监事和董事会秘书的出席情况 1、公司在任董事8人，出席8人，现场结合通讯方式出席8人； 二、议案审议情况 （一）非累积投票议案 1、议案名称：《关于取消监事会、修订〈公司章程〉及其附件并办理工商变更登记的议案》 审议结果：通过 表决情况： ■ 2、议案名称：《关于制定和修订部分公司治理制度的议案》 2.01、议案名称：《关于修 ...

汇宇制药(688553.SH)公告，公司及其子公司Seacross Pharma(Europe)Ltd.和Seacross Pharmaceuticals Ltd. 于近期分别收到丹麦药品管理局、德国联邦药品和医疗器械管理局、乌兹别克斯坦共和国药品监督管理 局、孟加拉国药品监督管理局分别核准签发的公司产品注射用紫杉醇(白蛋白结合型)、注射用环磷酰 胺、紫杉醇注射液、注射用唑来膦酸浓溶液、注射用阿扎胞苷的上市许可。 ...

智通财经APP讯，汇宇制药(688553.SH)公告，公司及其子公司 Seacross Pharma (Europe) Ltd.和 Seacross Pharmaceuticals Ltd.于近期分别收到丹麦药品管理局、德国联邦药品和医疗器械管理局、乌兹别克斯坦 共和国药品监督管理局、孟加拉国药品监督管理局分别核准签发的公司产品注射用紫杉醇(白蛋白结合 型)、注射用环磷酰胺、紫杉醇注射液、注射用唑来膦酸浓溶液、注射用阿扎胞苷的上市许可。 ...

人民财讯9月15日电，汇宇制药(688553)9月15日晚间公告，公司及子公司Seacross Pharma(Europe)Ltd.和 Seacross Pharmaceuticals Ltd.于近期分别收到丹麦药品管理局、德国联邦药品和医疗器械管理局、乌兹 别克斯坦共和国药品监督管理局、孟加拉国药品监督管理局分别核准签发的公司产品注射用紫杉醇(白 蛋白结合型)、注射用环磷酰胺、紫杉醇注射液、注射用唑来膦酸浓溶液、注射用阿扎胞苷的上市许 可。 ...

格隆汇9月15日丨汇宇制药(688553.SH)公布，公司及其子公司SeacrossPharma (Europe) Ltd.和 Seacross Pharmaceuticals Ltd.于近期分别收到丹麦药品管理局、德国联邦药品和医疗器械管理局、乌兹别克斯坦 共和国药品监督管理局、孟加拉国药品监督管理局分别核准签发的公司产品注射用紫杉醇(白蛋白结合 型)、注射用环磷酰胺、紫杉醇注射液、注射用唑来膦酸浓溶液、注射用阿扎胞苷的上市许可。 公司研发的注射用紫杉醇(白蛋白结合型)、注射用环磷酰胺、紫杉醇注射液、注射用唑来膦酸浓溶液、 注射用阿扎胞苷分别获得丹麦、德国、乌兹别克斯坦、孟加拉国的上市许可，有利于公司在国际市场产 品管线的丰富，提升市场的品牌形象，持续拓展国际业务的广度和深度，为国际市场的可持续发展进一 步夯实了基础。 ...

汇宇制药公告，公司及其子公司近期获得丹麦、德国、乌兹别克斯坦和孟加拉国的药品上市许可，包括 注射用紫杉醇、注射用环磷酰胺、紫杉醇注射液、注射用唑来膦酸浓溶液和注射用阿扎胞苷。这些药品 已分别在多国提交注册申请，并获得上市许可，有助于公司在国际市场上扩展产品线和提升品牌形象。 公司已进行产品上市销售的前期准备，但受市场竞争等因素影响，未来业绩不确定。 ...

Group 1 - Yitong Century won a bid for a communication engineering construction service project from China Mobile, with a total bid amount of 228 million yuan (including tax) [1] - Zhiyuan New Energy plans to repurchase shares worth between 33 million and 66 million yuan, with a maximum repurchase price of 22.00 yuan per share [1] - GAC Group reported April automobile sales of 116,400 units, a year-on-year decrease of 12.66% [2] - JAC Motors reported April automobile sales of 30,764 units, a year-on-year decrease of 3.55% [3] Group 2 - Fosun Pharma's subsidiary received FDA approval for a clinical trial of a live biotherapeutic product aimed at treating androgenetic alopecia [4] - Liangxin Co. obtained multiple patent certificates, including 2 invention patents and 32 utility model patents [5] - Sainuo Medical's two products received medical device registration certificates in Mexico and Ecuador [5] - Huayu Pharmaceutical's two products received marketing approvals in France and Spain [6] Group 3 - Shengnong Development reported April sales revenue of 1.533 billion yuan, a year-on-year increase of 0.68% [6] - Hasi Lian's potassium chloride and sodium chloride injection passed the consistency evaluation [7] - Shapuaisi received approval for a supplemental application for levofloxacin eye drops [9] - Tianyu Biological reported April sales revenue of 59.32 million yuan from pig sales [10] Group 4 - *ST Weihai was pre-awarded a project worth 108 million yuan [12] - Luoniushan reported April sales revenue of 125 million yuan from pig sales, a year-on-year increase of 12.72% [13] - Minhe Co. reported April sales revenue of 68.30 million yuan from chick sales, a year-on-year increase of 0.51% [14] Group 5 - Double Ring Technology's application for a specific stock issuance was approved by the Shenzhen Stock Exchange [15] - Hualu Hengsheng plans to repurchase shares worth between 200 million and 300 million yuan [16] - Baolong Technology plans to repurchase shares worth between 100 million and 200 million yuan [17] Group 6 - Huasheng Technology's subsidiary plans to sell shares of a company for 200 million yuan [24] - *ST Gengxing's controlling shareholder plans to increase holdings worth between 30 million and 60 million yuan [25] - Ruihuatai's shareholder plans to reduce holdings by up to 1% of the company's shares [26] Group 7 - Foton Motor reported April commercial vehicle sales of 54,816 units, a year-on-year increase of 21.63% [20] - China Merchants Bank plans to invest 15 billion yuan to establish a financial asset investment company [22] - Jinchengxin plans to invest approximately 231 million USD in the Alacran copper-gold-silver mine project [23] Group 8 - Zhongji United's controlling shareholder plans to reduce holdings by up to 2% of the company's shares [30] - Ningbo Huaxiang signed a strategic cooperation agreement to strengthen collaboration in various areas [31] - SMIC reported a net profit of 1.356 billion yuan for Q1 2025, a year-on-year increase of 166.5% [32] Group 9 - FAW Fuwi received a project notification to develop seat products for a luxury brand, with a total sales amount expected to be 1.39 billion yuan [33] - Huakang Clean won a bid for a purification project worth 64.425 million yuan [34] - Lihua Co. reported April sales revenue of 1.125 billion yuan from chicken sales [35]